HOTH
vs
S&P 500
HOTH
S&P 500
Over the past 12 months, HOTH has outperformed S&P 500, delivering a return of +33% compared to the S&P 500's +14% growth.
Stocks Performance
HOTH vs S&P 500
Performance Gap
HOTH vs S&P 500
Performance By Year
HOTH vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hoth Therapeutics Inc
Glance View
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The firm is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. The company is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.